Literature DB >> 31587001

Southeast Asian Pharmacogenomics Research Network (SEAPharm): Current Status and Perspectives.

Supatat Chumnumwat1, Zen Huat Lu2, Chonlaphat Sukasem3, Michael David Winther4,5, Francis R Capule6, Asma A Apos Tiyah Abdul Hamid7, Bibek Bhandari8, Usa Chaikledkaew1, Noppadol Chanhom9, Soranun Chantarangsu10, Angkana Charoenyingwattana11, Tong Thi Hang12, Tin Maung Hlaing13, Kyaw Soe Htun13, Jiraphun Jittikoon9, Ly Le12,14, Surakameth Mahasirimongkol15, Dzul Azri Mohamed Noor16, Jesus Shrestha8, Lakkana Suwannoi1, Pramote Tragulpiankit1, Saowalak Turongkaravee1, Sukanya Wattanapokayakit15, Phonepadith Xangsayarath17, Rika Yuliwulandari18, Shamsul Mohd Zain19, Wasun Chantratita20.   

Abstract

Pharmacogenomics (PGx) is increasingly being recognized as a potential tool for improving the efficacy and safety of drug therapy. Therefore, several efforts have been undertaken globally to facilitate the implementation process of PGx into routine clinical practice. Part of these efforts include the formation of PGx working groups working on PGx research, synthesis, and dissemination of PGx data and creation of PGx implementation strategies. In Asia, the Southeast Asian Pharmacogenomics Research Network (SEAPharm) is established to enable and strengthen PGx research among the various PGx communities within but not limited to countries in SEA; with the ultimate goal to support PGx implementation in the region. From the perspective of SEAPharm member countries, there are several key elements essential for PGx implementation at the national level. They include pharmacovigilance database, PGx research, health economics research, dedicated laboratory to support PGx testing for both research and clinical use, structured PGx education, and supportive national health policy. The status of these essential elements is presented here to provide a broad picture of the readiness for PGx implementation among the SEAPharm member countries, and to strengthen the PGx research network and practice in this region.
© 2019 S. Karger AG, Basel.

Keywords:  Drug-induced liver injury; Pharmacogenomics; Southeast Asia; Stevens-Johnson syndrome; Toxic epidermal necrolysis

Mesh:

Year:  2019        PMID: 31587001     DOI: 10.1159/000502916

Source DB:  PubMed          Journal:  Public Health Genomics        ISSN: 1662-4246            Impact factor:   2.000


  11 in total

Review 1.  Clinical implementation of drug metabolizing gene-based therapeutic interventions worldwide.

Authors:  Evangelia Eirini Tsermpini; Zeina N Al-Mahayri; Bassam R Ali; George P Patrinos
Journal:  Hum Genet       Date:  2021-10-01       Impact factor: 4.132

2.  PharmaKoVariome database for supporting genetic testing.

Authors:  Jungeun Kim; Jae-Pil Choi; Min Sun Kim; Jong Bhak
Journal:  Database (Oxford)       Date:  2022-10-18       Impact factor: 4.462

3.  A Roadmap for Future Parkinson's Pharmacogenomics in Asia.

Authors:  Muhammad Akbar; Gita Vita Soraya; Zulvikar Syambani Ulhaq; Andi Kurnia Bintang
Journal:  Front Aging Neurosci       Date:  2022-05-17       Impact factor: 5.702

Review 4.  Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Lola Corzo; Natalia Cacabelos; Juan C Carril
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

5.  Prevalence of pharmacogenomic variants in 100 pharmacogenes among Southeast Asian populations under the collaboration of the Southeast Asian Pharmacogenomics Research Network (SEAPharm).

Authors:  Chakkaphan Runcharoen; Koya Fukunaga; Insee Sensorn; Nareenart Iemwimangsa; Sommon Klumsathian; Hang Tong; Nam Sy Vo; Ly Le; Tin Maung Hlaing; Myo Thant; Shamsul Mohd Zain; Zahurin Mohamed; Yuh-Fen Pung; Francis Capule; Jose Nevado; Catherine Lynn Silao; Zeina N Al-Mahayri; Bassam R Ali; Rika Yuliwulandari; Kinasih Prayuni; Hilyatuz Zahroh; Dzul Azri Mohamed Noor; Phonepadith Xangsayarath; Dalouny Xayavong; Sengchanh Kounnavong; Somphou Sayasone; Zoe Kordou; Ioannis Liopetas; Athina Tsikrika; Evangelia-Eirini Tsermpini; Maria Koromina; Christina Mitropoulou; George P Patrinos; Aumpika Kesornsit; Angkana Charoenyingwattana; Sukanya Wattanapokayakit; Surakameth Mahasirimongkol; Taisei Mushiroda; Wasun Chantratita
Journal:  Hum Genome Var       Date:  2021-02-04

6.  Variation in 100 relevant pharmacogenes among emiratis with insights from understudied populations.

Authors:  Zeina N Al-Mahayri; George P Patrinos; Sukanya Wattanapokayakit; Nareenart Iemwimangsa; Koya Fukunaga; Taisei Mushiroda; Wasun Chantratita; Bassam R Ali
Journal:  Sci Rep       Date:  2020-12-04       Impact factor: 4.379

7.  Editorial: Pharmacogenetics and Pharmacogenomics in Latin America: Ethnic Variability, New Insights in Advances and Perspectives: A RELIVAF-CYTED Initiative.

Authors:  Patricia Esperón; Matías F Martínez; María A Redal; Alberto Lazarowski; Andrés López-Cortés; Nelson M Varela; Luis A Quiñones
Journal:  Front Pharmacol       Date:  2022-01-11       Impact factor: 5.810

8.  Genetic Variation of G6PD and CYP2D6: Clinical Implications on the Use of Primaquine for Elimination of Plasmodium vivax.

Authors:  Alexandra G A Stewart; Peter A Zimmerman; James S McCarthy
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

Review 9.  From pharmacogenetics to pharmaco-omics: Milestones and future directions.

Authors:  Chiara Auwerx; Marie C Sadler; Alexandre Reymond; Zoltán Kutalik
Journal:  HGG Adv       Date:  2022-03-16

10.  Implementation of HLA-B*15:02 Genotyping as Standard-of-Care for Reducing Carbamazepine/Oxcarbazepine Induced Cutaneous Adverse Drug Reactions in Thailand.

Authors:  Kanyawan Tiwattanon; Shobana John; Napatrupron Koomdee; Pimonpan Jinda; Jiratha Rachanakul; Thawinee Jantararoungtong; Nutthan Nuntharadthanaphong; Chiraphat Kloypan; Mohitosh Biswas; Apisit Boongird; Chonlaphat Sukasem
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.